Crizotinib in MET-deregulated or ROS1-rearranged pretreated non–small cell lung cancer (METROS): A phase II, prospective, multicenter, two-arms trial

L. Landi, R. Chiari, M. Tiseo, F. D'Inca, C. Dazzi, A. Chella, A. Delmonte, L. Bonanno, D. Giannarelli, D.L. Cortinovis, F. de Marinis, G. Borra, A. Morabito, C. Gridelli, D. Galetta, F. Barbieri, F. Grossi, E. Capelletto, G. Minuti, F. MazzoniC. Verusio, E. Bria, G. Al, R. Bruno, A. Proietti, G. Fontanini, L. Crino, F. Cappuzzo

Research output: Contribution to journalArticlepeer-review

Cite this